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OBJECTIVES: The objective was to evaluate the direct and indirect costs of asthma 
in working US adults. METHODS: Asthma patients with q1 primary asthma diagno-
sis, or q1 asthma diagnosis any level and q1 asthma prescription, or q2 asthma diag-
noses any level between January 2003 and December 2005 in the Thomson Reuters 
MarketScan Commercial Database and Health and Productivity Management Data-
base were extracted. Patients were 18–64 years old, had full-time employment, were
eligible for absence, or short-term disability (STD), or workers’ compensation (WC)
and were continuously enrolled 12-month pre/post the index date (ﬁ rst asthma
diagnosis or asthma medication claim). Those with emphysema or COPD were 
excluded. The controls had no asthma claim and met the same inclusion and exclusion
criteria. An index date was assigned to controls by adding a number to January 2003 
that was randomly drawn from a pool of days between January 2003 and index date 
for each asthma patient. Propensity score techniques were used to match asthma 
patients to controls based on baseline demographic and clinical characteristics.
RESULTS: A total of 13,379 asthma patients were matched to 13,379 controls com-
prising of 3,453 patients with absence eligibility, 8,497 with STD eligibility and 8,264 
with WC eligibility in each of the asthma and control group. Most baseline charac-
teristics after matching were very similar. Asthma patients had $1,988 higher direct
medical costs than matched controls (p  0.001) during the 12-month follow up. They
experienced 1.2 more absence days (p  0.0142), 2.2 more STD days (p  0.001) and 
1.3 more WC days (p  0.001) than controls. This translated into $166 (p  0.041), 
$248 (p  0.001) and $59 (p  0.009) more in indirect costs respectively. CONCLU-
SIONS: Asthma patients experience signiﬁ cantly greater work loss and medical costs 
than patients without asthma. Asthma treatments can potentially beneﬁ t in reducing
absenteeism and costs.
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OBJECTIVES: Examine outcomes and costs for persistent asthma patients who 
initiated therapy with beclomethasone dipropionate (BD) or ﬂ uticasone propionate
(FP). METHODS: MedStat’s Commercial Claims and Encounter Database (July 1, 
2002 – June 30, 2007) was utilized. Patients who initiated therapy with BD or FP
(ﬁ rst use  index date) and met the following criteria: a) no receipt of other study 
medication in the 1 year post-period; b) persistent asthma in the 1 year pre-period; c) 
age 5–64; d) no diagnosis of COPD; and e) continuous insurance coverage from 1
year pre through 1 year post-period were included. Multivariate regressions (N 
13,968) examined the probability of an ER visit or hospitalization, probability of 
reaching alternative adherence thresholds and annual costs. RESULTS: Receipt of BD, 
compared to FP, was associated with a 17% reduction in the odds of an ER visit (OR 
 0.834, 95% CI 0.751–0.925), 30% reduction in the odds of an asthma-related ER 
visit (OR  0.697, 95% CI 0.571–0.852), as well as a signiﬁ cant increase in the 
odds of obtaining a medication possession ratio (MPR) of at least 50% (OR  1.324;
95% CI 1.164–1.506) or 75% (OR  1.311; 95% CI 1.072–1.604). Total medical 
costs ($5,063 v $5,377, p  0.0042), drug costs ($2336 vs. $2581, P  0.0001) and 
ER costs ($185 vs. $249, p  0.0001) were signiﬁ cantly lower among the BD cohort. 
Asthma-related outpatient ($191 vs. $224, P  0.0001) and ER costs ($28 vs. $45,
P  0.001) were signiﬁ cantly lower in the BD group while asthma-related inpatient
($59 vs. $101 P  0.0001) and drug costs ($451 vs. $540, P  0.0001) were signiﬁ -
cantly lower in the FP cohort. CONCLUSIONS: Results indicate that receipt of 
BD, compared to receipt of FP, is associated with a decreased probability of ER
visits or asthma-related ER visits, and higher odds of reaching a MPR threshold of 
0.50 or 0.75. Receipt of BD was also associated with lower annual total medical and 
drug costs.
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SIMULATING COST-EFFECTIVENESS OF STEPPED CARE VERSUS 
REPEAT CARE IN SMOKING CESSATION
Franklin BE, Klesges R
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OBJECTIVES: Smoking is the leading avoidable cause of premature morbidity and
mortality in the United States, attributable to over 400,000 annual deaths and $167
billion in health care costs. Nicotine addiction remains a key barrier to smoking ces-
sation; for this reason, repeated intervention and multiple quit attempts are necessary.
Stepped care is possibly a viable intensive approach for achieving long-term smoking
cessation. This study uses modeling techniques to predict outcomes of a current study
of stepped care in smoking cessation. It is expected that, though more costly, incre-
mental cost-effectiveness of stepped care will fall well short of accepted thresholds. 
METHODS: A simulation model was created in TreeAge to replicate the Step Care 
study. Both arms receive pharmacotherapy and counseling; these therapies intensify in
the step care arm. Various data sources were used to estimate transition probabilities 
and costs. The model was run 1,000 times to produce estimates of cost-effectiveness
of the stepped care regimen relative to repeat therapy in producing point-prevalent 
cessation. RESULTS: As expected, the model produced a favorable incremental cost-
effectiveness ratio (ICER) for stepped care relative to repeat care ($941/quit). Step care
and Recycle arms produced mean costs of $740 (95% CI: $540–840) and $665 (95% 
CI: $520–740), respectively. On average, 31% of step care patients achieved point-
prevalent cessation at study end, compared to only 23% of patients in the recycle. In 
the simulation, 37% of step care patients required each step of therapy; in the recycle
arm, an average 2.2 quit attempts were made with patch therapy. CONCLUSIONS:
The results of the Step Care simulation are promising for achieving progress in tobacco
cessation efforts. The population represented in the Step Care study is a difﬁ cult-to-
treat population—predominately low-income smokers with high rates of nicotine 
dependence. Treatment guidelines suggest this population to be appropriate for more
intensive intervention.
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OBJECTIVES: Evaluating the cost-effectiveness and cost-utility of a pharmacological
intervention for smoking cessation comparing varenicline, bupropion, nicotine 
replacement therapy (NRT) and unaided cessation in Colombia. METHODS: A full
economic evaluation was made using the BENESCO (Beneﬁ ts of Smoking Cessation
on Outcomes) model. Such model simulates a cohort of smokers making a single 
attempt to quit, using different strategies. The model was inputted demographic and 
epidemiological data corresponding to the Colombian adult population. A systematic 
review was made to identify the effectiveness of varenicline and the alternative inter-
ventions. This review was complemented by consulting available data sources in 
Colombia in order to estimate disease burden for lung cancer, chronic obstructive 
pulmonary disease, coronary hearth disease and stroke. The cost of attending these
diseases was estimated from a third-payer perspective using HMO and health care 
provider records. The medicament’s cost corresponded to the average of a survey of 
prices regarding a set of pharmaceutical vendors representative of the market. It was 
assumed that unaided cessation involved no cost for the third-payer. The clinical and 
economic results of the four intervention options were projected using the BENESCO
model at 2-, 5-, 10- and 20-year time-horizons; such projections were used to calculate
incremental cost-effectiveness (ICER) and cost-utility (ICUR) ratios. Future clinical 
and economic outcomes were discounted at a 3% annual rate; all costs were assessed 
in US$2007. RESULTS: Varenicline dominated NRT and bupropion considering all 
time-horizons. When compared to unaided cessation, dominance was found in 20-year 
and lifetime projections; in 10-year projections it was found an ICUR  USD$11,711 
for QALY gained and ICER  USD$24,349 per life year gained; however, varenicline 
was not cost-effective when evaluating 2–5 year projections. CONCLUSIONS:
Supportive pharmacological interventions for smoking cessation could be promising 
alternatives for controlling the diseases being evaluated. Varenicline is the most cost-
effective of the interventions currently available in Colombia.
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A COST-CONSEQUENCE ANALYSIS COMPARING AN ESTABLISHED AND 
A NOVEL EPINEPHRINE AUTO-INJECTOR FOR ANAPHYLAXIS
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OBJECTIVES: Anaphylaxis is a rare yet potentially fatal allergic reaction. While at-
risk patients are advised to carry self-injectable epinephrine with them at all times,
many do not. We examined the costs and consequences of using an established device
versus a novel device being developed by Intelliject, Inc. for treatment of a uniphasic 
anaphylactic reaction. Because of its smaller size and user-friendly design, the new 
device is expected to be carried and used correctly more often than the established
device. METHODS: A decision tree model for costs and consequences was created 
using DATA TreeAge 3.0. Consequences included recovering without visiting the
emergency department (ED), ED use, and hospitalizations. Direct costs were estimated 
for device use, ED use, and hospitalizations. Data were obtained from the literature,
HCUPnet (online query tool for Healthcare Cost and Utilization Project), and Intelli-
ject’s clinical study programs. For the purpose of this analysis, the price of the new
device was assumed to be twice that of the established device. One-way sensitivity
analyses were conducted for patients’ probabilities of carrying the device and using it 
correctly and of recovery and death after using the device incorrectly. RESULTS: Base 
case results per 100 patients indicate that the new device would lead to more patients
recovering without visiting the ED (57 vs. 35), similar rates of ED use without hospi-
talization (7) and fewer hospitalizations (2 vs. 4). The results also indicate higher 
device costs ($15,837 vs. $6,291) and same ED use costs ($9,375) but lower costs for 
hospitalizations ($15,303 vs. $30,606); leading to lower total costs for the new device 
($40,515 vs. $46,272). Sensitivity analyses indicate that the new device would have 
lower total costs and lead to better consequences under most tested assumptions.
CONCLUSIONS: At the assumed price premium, the new device provided lower total
costs, higher recovery rate as well as fewer hospitalizations.
